De Novo device
Cell-Free DNA BCT
Streck, Inc. · Blood Collection Device For Cell-Free Nucleic Acid (QMA, Class II) · First FDA decision Aug 7, 2020, newest Jul 26, 2024Cancer detection and genomic testing
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
De Novo pathway
Device trials
2
Naming "Cell-Free DNA BCT"
MAUDE reports
0
Brand "Cell-Free DNA BCT", since 2015
PubMed studies
23
Mentioning "Cell-Free DNA BCT"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Cell-Free DNA BCT
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 2 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Cell-Free DNA BCT", any status and sponsor, newest update first.
Universal DiagnosticsNot on our public-company list
NCT06059963 · 12,000 participants (planned) · Start Jan 18, 2024 · Primary completion Oct 30, 2026
Device: Signal-C™ · For: Colorectal Cancer; Advanced Adenocarcinoma
Sites: Raonoke, Virginia
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Cell-Free DNA BCT", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QMA
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Cell-Free DNA BCT"[tiab]. The summary above synthesizes these.
- Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol.
Sorber L, Zwaenepoel K, Jacobs J, et al. · Cancers (Basel) · 2019
- Comparison of Roche Cell-Free DNA collection Tubes ® to Streck Cell-Free DNA BCT ® s for sample stability using healthy volunteers.
Parackal S, Zou D, Day R, et al. · Pract Lab Med · 2019
- Two Commercially Available Blood-Stabilization Reagents Serve as Potent Inactivators of Coronaviruses.
O'Connor JJ, Voth L, Athmer J, et al. · Pathogens · 2023
- Performance of ImproGene cfDNA blood collection tubes for mutation analysis in cancer patients.
Zhang S, Zhou D, Li S, et al. · Scand J Clin Lab Invest · 2022
- Evaluation of The Relationship between Cell-Free DNA Fetal Fraction of The Circulatory System and Fetal and Maternal Pregnancy Prognosis: A Prospective Study.
Rezaie Keikhaie K, Moshfeghi M, Rezaie Kahkhaie L, et al. · Int J Fertil Steril · 2023
- Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project.
Bardol T, Dujon AM, Taly V, et al. · BMC Cancer · 2024Multicenter Study, Observational Study
- Blood Collection and Cell-Free DNA Isolation Methods Influence the Sensitivity of Liquid Biopsy Analysis for Colorectal Cancer Detection.
Barták BK, Kalmár A, Galamb O, et al. · Pathol Oncol Res · 2019
- Evaluating the prognostic potential of circulating cell-free DNA in advanced thyroid cancer.
Wijewardene A, Clifton-Bligh RJ, Wang B, et al. · Endocr Relat Cancer · 2025
- Genome-wide study of the effect of blood collection tubes on the cell-free DNA methylome.
Van Paemel R, De Koker A, Caggiano C, et al. · Epigenetics · 2021Research Support, Non-U.S. Gov't
- Toward a Robust Cell-free DNA Isolation Protocol for Next-Generation Sequencing Applications in a Clinical Molecular Diagnostics Setting.
Apweiler M, Broche J, Loitz M, et al. · J Mol Diagn · 2026
- Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients.
Risberg B, Tsui DWY, Biggs H, et al. · J Mol Diagn · 2018Research Support, Non-U.S. Gov't
- STR profiling and Copy Number Variation analysis on single, preserved cells using current Whole Genome Amplification methods.
Vander Plaetsen AS, Deleye L, Cornelis S, et al. · Sci Rep · 2017Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.